This website uses its own and third party technical cookies, solely to ensure enhanced navigation and to gather anonymous statistical navigation data without any user profiling.

If you wish to learn more or deny consent to all or some cookies click here.

If you access any element below this banner you automatically consent to the use of cookies.



Since its foundation, in 1997 as Abiogen’s Research Centre, Galileo Research has worked on major studies in the field of osteo-articular metabolism, resulting in the discovery of Bisphosphonates for the treatment of bone pathologies.


This acitivty culminated with the transfer of the worldwide rights of Alendronate to Merck Sharp & Dohme and of Clodronate to Boehringer Mannheim. This success encouraged the Company to enter fields of pharmacology where many needs are still to be met and where growing knowledge can create openings to new important achievements.


It is with this assumption that the research projects have been geared towards CNS diseases, oncology and degenerative pathologies, developing small organic molecules, biologicals and advanced therapies. Over these years, we have matured a vast experience and know-how in innovative projects/products and technologies, in cooperation with international partners, without abandoning those areas that have brought success and results in the past.